The largest community of pharma leaders

Lucence Launches DeepMARK™ for Profiling of SARS-CoV-2 Subgenomic RNA

SINGAPORE–(BUSINESS WIRE)–Molecular diagnostics company Lucence today announced the availability of the world’s first assay kit to directly profile SARS-CoV-2 subgenomic RNA (sgRNA), a marker of active viral replication1, from clinical samples. DeepMARK™ utilizes Lucence’s proprietary ultrasensitive next-generation sequencing (NGS) technology, AmpliMARK™, to concurrently detect and analyze the genome and transcriptome of SARS-CoV-2. Pinpointing sources of unlinked SARS-CoV-2 cases supports ra


Recent Articles